F&V Capital Management LLC Sells 147,040 Shares of Gilead Sciences, Inc. $GILD

F&V Capital Management LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 96.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,200 shares of the biopharmaceutical company’s stock after selling 147,040 shares during the quarter. F&V Capital Management LLC’s holdings in Gilead Sciences were worth $687,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in GILD. Southland Equity Partners LLC grew its stake in shares of Gilead Sciences by 2.9% during the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after buying an additional 92 shares during the last quarter. Twelve Points Wealth Management LLC grew its stake in shares of Gilead Sciences by 1.5% during the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after buying an additional 98 shares during the last quarter. Argentarii LLC grew its stake in shares of Gilead Sciences by 3.0% during the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after buying an additional 99 shares during the last quarter. Perkins Coie Trust Co grew its stake in shares of Gilead Sciences by 2.6% during the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock valued at $435,000 after buying an additional 100 shares during the last quarter. Finally, Investment Research & Advisory Group Inc. grew its stake in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 100 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $110.56 on Friday. Gilead Sciences, Inc. has a 52 week low of $83.98 and a 52 week high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $137.18 billion, a PE ratio of 22.02, a price-to-earnings-growth ratio of 0.76 and a beta of 0.34. The stock’s 50-day moving average price is $114.42 and its 200-day moving average price is $109.91.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same period last year, the firm earned $2.01 EPS. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.9%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,000 shares of company stock worth $9,402,130. Insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on GILD. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $108.00 to $127.00 in a research note on Friday, August 8th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target for the company in a report on Tuesday, August 19th. Finally, Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.